

# Ultrasound Therapy In Cardiac Amyloidosis

NCT04667494

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 4
<b>Sponsor</b>	Brigham and Women's Hospital
<b>Enrollment</b>	70 participants

## Key Eligibility Criteria

---

### Inclusion (12)

- Age  $\geq$  18 years for AL-CA,  $\geq$  65 years for ATTR-CA,  $\geq$  65 years for controls
  - Willing and able to provide consent
  - Diagnosis of systemic light chain amyloidosis by standard criteria (see below) and in hematological remission (normal serum free light chain levels)
  - (immunofixation of serum and urine, IgG free light chain (FLC) assay, a biopsy of fat pad/ bone marrow, or organ biopsy, followed by typing of the light chain using immunohistochemistry or immunogold assay with confirmation by Mass spectroscopy as needed) AND
  - proof of cardiac involvement by AL amyloidosis
- ... and 7 more (see full listing online)

### Exclusion (23)

- Hemodynamic instability
  - Severe claustrophobia despite use of sedatives
  - Decompensated heart failure (unable to lie flat for 1 hour)
  - Concomitant non-ischemic non-amyloid heart disease (valvular heart disease or dilated cardiomyopathy)
  - Severe valve stenosis or regurgitation in the aortic, mitral or tricuspid valves, including prior valve replacement
- ... and 18 more (see full listing online)

## Locations (1 total)

---

Brigham and Women's Hospital, Boston, Massachusetts, United States